October 2018 Review
ICER developed a report on anti-androgen drugs for high risk prostate cancer, including the following therapies: enzalutamide (Xtandi®, Astellas and Medivation), abiraterone acetate (Zytiga®, Janssen), apalutamide (Erleada™, Janssen).
For questions or additional information, please contact firstname.lastname@example.org
- September 2009: Active surveillance and Radical prostatectomy
- December 2008: Brachytherapy and Proton beam therapy
Proton beam therapy was also the subject of an evidence review by ICER for the Washington State Health Care Authority in May 2014.
- November 2007: Intensity modulated radiation therapy (IMRT)
View the Key Stakeholders List.
Below you will find the final documents from the assessment review process: